Arthritis drug halted early in trial for rare tumor syndrome
NCT ID NCT05605587
Summary
This study tested whether leflunomide, a drug used for rheumatoid arthritis, could slow or shrink tumors in people with a rare genetic condition called MEN1. MEN1 causes tumors in multiple glands and reduces life expectancy. The trial aimed to see if six months of daily leflunomide treatment could control these tumors, but it was stopped early after enrolling only three participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEN1 GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Unispital Basel
Basel, 4053, Switzerland
Conditions
Explore the condition pages connected to this study.